Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in JIA-Associated Uveitis or Chronic Anterior ANA-Positive Uveitis
NCT04088409Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2019
- Primary completion
- Jul 2023
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 5
01
Overview
A Phase 3 trial of baricitinib in juvenile idiopathic arthritis-associated uveitis (JIAU), chronic anterior uveitis (CAU), sponsored by Eli Lilly and Company. Started Oct 2019; status: active, not recruiting.
02
Drugs
baricitinib
03
Conditions
juvenile idiopathic arthritis-associated uveitis (JIAU)chronic anterior uveitis (CAU)
Beyond the preview
Go deeper on NCT04088409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04088409.